Isocucurbitacin B inhibits glioma growth through PI3K/AKT pathways and increases glioma sensitivity to TMZ by inhibiting hsa-mir-1286a

Abstract

Aim: Glioma accounts for 81% of all cancers of the nervous system cancers and presents one of the most drug-resistant malignancies, resulting in a relatively high mortality rate. Despite extensive efforts, the complete treatment options for glioma remain elusive. The effect of isocucurbitacin B (isocuB), a natural compound extracted from melon pedicels, on glioma has not been investigated. This study aims to investigate the inhibitory effect of isocuB on glioma and elucidate its underlying mechanisms, with the objective of developing it as a potential therapeutic agent for glioma.

Methods: We used network pharmacology and bioinformatics analysis to predict potential targets and associated pathways of isocuB in glioma. Subsequently, the inhibitory effect of isocuB on glioma and its related mechanisms were assessed through Counting Kit-8 (CCK-8), wound healing, transwell, Western blot (WB), reverse transcription-quantitative polymerase chain reaction (RT-qPCR), and other in vitro experiments, alongside tumor formation experiments in nude mice.

Results: Based on this investigation, it suggested that isocuB might inhibit the growth of gliomas through the PI3K-AKT and MAPK pathways. Additionally, we proposed that isocuB may enhance glioma drug sensitivity to temozolomide (TMZ) via modulation of hsa-mir-1286a. The CCK-8 assay revealed that isocuB exhibited inhibitory effects on U251 and U87 proliferation and outperformed TMZ. Wound healing and transwell experiments showed that isocuB inhibited the invasion and migration of U251 cells by suppressing the activity of MMP-2/9, N-cadherin, and Vimentin. The TdT-mediated dUTP-biotin nick end labeling (TUNEL) and flow cytometry (FCM) assays revealed that isocuB induced cell apoptosis through inhibition of BCL-2. Subsequently, we conducted RT-qPCR and WB experiments, which revealed that PI3K/AKT and MAPK pathways might be involved in the mechanism of the inhibition isocuB on glioma. Additionally, isocuB promoted the sensitivity of glioma U251 to TMZ by inhibiting hsa-mir-1286a. Furthermore, we constructed TMZ-resistant U251 strains and demonstrated effective inhibition by isocuB against these resistant strains. Finally, we confirmed that isocuB can inhibit tumor growth in vivo through experiments on tumors in nude mice.

Conclusion: IsocuB may protect against glioma by acting on the PI3K/AKT and MAPK pathways and promote the sensitivity of glioma U251 to TMZ by inhibiting hsa-mir-1286a.

Keywords

Isocucurbitacin B / glioma / network pharmacology / hsa-mir-1286a / drug sensitivity

References

[1] Berger TR,Lang-Orsini M.World Health Organization 2021 classification of central nervous system tumors and implications for therapy for adult-type gliomas: a review.JAMA Oncol2022;8:1493-501

[2] Wang L,Fan H.Bifidobacterium lactis combined with Lactobacillus plantarum inhibit glioma growth in mice through modulating PI3K/AKT pathway and gut microbiota. Front Microbiol 2022;13:986837. PMCID:PMC9486703

[3] Louis DN,Wesseling P.The 2021 WHO classification of tumors of the central nervous system: a summary.Neuro Oncol2021;23:1231-51 PMCID:PMC8328013

[4] Cai X,Mu P.Sequence-defined nanotubes assembled from IR780-conjugated peptoids for chemophototherapy of malignant glioma.Research2021;2021:9861384 PMCID:PMC8147695

[5] Xu S,Li X,Liu Z.Immunotherapy for glioma: current management and future application.Cancer Lett2020;476:1-12

[6] Stupp R,van den Bent MJ.European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy GroupsNational Cancer Institute of Canada Clinical Trials GroupRadiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.Oncol Times2005;27:15-6

[7] Han M,Fan H,Peng C.Regulated cell death in glioma: promising targets for natural small-molecule compounds.Front Oncol2024;14:1273841 PMCID:PMC10830839

[8] Tamtaji OR,Razzaghi N,Barati E.Quercetin and glioma: which signaling pathways are involved?.Curr Mol Pharmacol2022;15:962-8

[9] Liu A,Song C.Isoliquiritigenin inhibits circ0030018 to suppress glioma tumorigenesis via the miR-1236/HER2 signaling pathway.MedComm2023;4:e282 PMCID:PMC10220153

[10] Buyel JF.Plants as sources of natural and recombinant anti-cancer agents.Biotechnol Adv2018;36:506-20

[11] Li Y,Yao Y.Potential of cucurbitacin as an anticancer drug.Biomed Pharmacother2023;168:115707

[12] Dai S,Zhao X.Cucurbitacin B: a review of its pharmacology, toxicity, and pharmacokinetics.Pharmacol Res2023;187:106587

[13] Yuan R,Wang QQ.Cucurbitacin B inhibits non-small cell lung cancer in vivo and in vitro by triggering TLR4/NLRP3/GSDMD-dependent pyroptosis.Pharmacol Res2021;170:105748

[14] Liu JH,Cao L,Zhang ZH.Cucurbitacin B regulates lung cancer cell proliferation and apoptosis via inhibiting the IL-6/STAT3 pathway through the lncRNA XIST/miR-let-7c axis.Pharm Biol2022;60:154-62 PMCID:PMC8725843

[15] Zhang H,Wei H,Sheng D.Cucurbitacin B controls M2 macrophage polarization to suppresses metastasis via targeting JAK-2/STAT3 signalling pathway in colorectal cancer.J Ethnopharmacol2022;287:114915

[16] Dandawate P,Panovich P.Cucurbitacin B and I inhibits colon cancer growth by targeting the Notch signaling pathway.Sci Rep2020;10:1290 PMCID:PMC6987129

[17] Yin D,Xing H.Cucurbitacin B markedly inhibits growth and rapidly affects the cytoskeleton in glioblastoma multiforme.Int J Cancer2008;123:1364-75

[18] Nogales C,List M,Casas AI.Network pharmacology: curing causal mechanisms instead of treating symptoms.Trends Pharmacol Sci2022;43:136-50

[19] Pinzi L.Molecular docking: shifting paradigms in drug discovery.Int J Mol Sci2019;20:4331 PMCID:PMC6769923

[20] Ren L,Liu J.Network pharmacology study of traditional Chinese medicines for stroke treatment and effective constituents screening.J Ethnopharmacol2019;242:112044

[21] He B,Cai Q.miRNA-based biomarkers, therapies, and resistance in cancer.Int J Biol Sci2020;16:2628-47 PMCID:PMC7415433

[22] WMA. WMA Declaration of Helsinki - Ethical principles for medical research involving human subjects. Available from: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/. [Last accessed on 26 Apr 2024]

[23] Percie du Sert N,Ahluwalia A.The ARRIVE guidelines 2.0: updated guidelines for reporting animal research.PLoS Biol2020;18:e3000410

[24] Zhou Y,Pache L.Metascape provides a biologist-oriented resource for the analysis of systems-level datasets.Nat Commun2019;10:1523 PMCID:PMC6447622

[25] Jabłońska-Trypuć A,Rosochacki S.Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs.J Enzyme Inhib Med Chem2016;31:177-83

[26] Polyak K.Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits.Nat Rev Cancer2009;9:265-73

[27] Zheng Z,Hou X.Potential roles and molecular mechanisms of phytochemicals against cancer.Food Funct2022;13:9208-25

[28] Yuan Z,Leng T.Progress and prospects of research ideas and methods in the network pharmacology of traditional Chinese medicine.J Pharm Pharm Sci2022;25:218-26

[29] Zhou J,Liu B.lncRNA XLOC013218 promotes cell proliferation and TMZ resistance by targeting the PIK3R2-mediated PI3K/AKT pathway in glioma.Cancer Sci2022;113:2681-92 PMCID:PMC9357648

[30] An J,Han M,Xie J.Exploring the mechanisms of neurotoxicity caused by fuzi using network pharmacology and molecular docking.Front Pharmacol2022;13:961012 PMCID:PMC9468872

[31] Reinhardt A,Schrimpf D.Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations.Acta Neuropathol2018;136:273-91

[32] Yu H,Herrmann A,Jove R.Revisiting STAT3 signalling in cancer: new and unexpected biological functions.Nat Rev Cancer2014;14:736-46

[33] Piperi C,Papavassiliou AG.Pivotal role of STAT3 in shaping glioblastoma immune microenvironment.Cells2019;8:1398 PMCID:PMC6912524

[34] Venkata NG,Cabot PJ,Monteith GR.Mono(2-ethylhexyl)phthalate and mono-n-butyl phthalate activation of peroxisome proliferator activated-receptors alpha and gamma in breast.Toxicol Lett2006;163:224-34

[35] Leng J,Niu Y.Low-dose mono(2-ethylhexyl) phthalate promotes ovarian cancer development through PPARα-dependent PI3K/Akt/NF-κB pathway.Sci Total Environ2021;790:147990

[36] Zhang R,Zhang S.RXRα provokes tumor suppression through p53/p21/p16 and PI3K-AKT signaling pathways during stem cell differentiation and in cancer cells.Cell Death Dis2018;9:532 PMCID:PMC5945609

[37] Gagliardi PA,Primo L.PDK1: at the crossroad of cancer signaling pathways.Semin Cancer Biol2018;48:27-35

[38] Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, González-Barón M. PI3K/Akt signalling pathway and cancer.Cancer Treat Rev2004;30:193-204

[39] Tang J,Liu Y.Arsenic trioxide induces expression of BCL-2 expression via NF-κB and p38 MAPK signaling pathways in BEAS-2B cells during apoptosis.Ecotoxicol Environ Saf2021;222:112531

[40] Hou Y,Wan W,Pu X.Resveratrol provides neuroprotection by regulating the JAK2/STAT3/PI3K/AKT/mTOR pathway after stroke in rats.Genes Dis2018;5:245-55 PMCID:PMC6176158

[41] Li X,Chen H.Melanoma stem cells promote metastasis via exosomal miR-1268a inactivation of autophagy.Biol Res2022;55:29 PMCID:PMC9526915

[42] Li Y,Ren J.miR-1268a regulates ABCC1 expression to mediate temozolomide resistance in glioblastoma.J Neurooncol2018;138:499-508

[43] Lu YL,Huang XY.Prognostic significance of miR-1268a expression and its beneficial effects for post-operative adjuvant transarterial chemoembolization in hepatocellular carcinoma.Sci Rep2016;6:36104 PMCID:PMC5086876